Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 References 2 Further reading

Lilotomab

●中文 Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Lilotomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	CD37
Clinical data
Other names	Tetulomab, HH1
ATC code	none
Identifiers
CAS Number	1453362-55-4 1453362-90-7 (lutetium (¹⁷⁷Lu) lilotomab satetraxetan)
ChemSpider	none
UNII	58I6YNR7BV
KEGG	D12125

Lilotomab (formerly tetulomab, HH1)^[1] is a murine monoclonal antibody against CD37,^[2]aglycoprotein which is expressed on the surface of mature human B cells.^[3] It was generated at the Norwegian Radium Hospital.^[3]

As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA.^[2] This compound is called ¹⁷⁷Lu-HH1 or lutetium (¹⁷⁷Lu) lilotomab satetraxetan (trade name Betalutin).^[1] As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway.^[4]

The satetraxetan structure chelating lutetium-177^[5]

References

[edit]

^ ^a ^b "Lutetium (177lu) lilotomab satetraxetan - Nordic Nanovector". Adis Insight. Springer Nature Switzerland AG. Retrieved 1 September 2016.

^ ^a ^b "Recommended INN List 74" (PDF). WHO Drug Information. 29 (3). 2015.

^ ^a ^b Robak T, Robak P (May 2014). "Anti-CD37 antibodies for chronic lymphocytic leukemia". Expert Opinion on Biological Therapy. 14 (5): 651–61. doi:10.1517/14712598.2014.890182. PMID 24555705. S2CID 19987961.

^ "EudraCT Number: 2011-000033-36". EU Clinical Trials Registry. Treatment of lymphoma with targeted internal radiation therapy (Betalutin)

^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4): 515. 2014.

Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J (March 2013). "Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma". Current Radiopharmaceuticals. 6 (1): 20–7. doi:10.2174/1874471011306010004. PMC 3624777. PMID 23256748.

This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Atezolizumab Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab^# Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM

^‡Withdrawn from market

Clinical trials:

^†Phase III
^§Never to phase III

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lilotomab&oldid=1173861988" Categories: ●Drugs not assigned an ATC code ●Experimental cancer drugs ●Radiopharmaceuticals ●Lutetium complexes ●Antineoplastic and immunomodulating drug stubs ●Monoclonal antibody stubs Hidden categories: ●Articles with short description ●Short description is different from Wikidata ●Chemicals that do not have a ChemSpider ID assigned ●Articles without EBI source ●Chemical pages without DrugBank identifier ●Articles without InChI source ●Drugs with no legal status ●Articles containing unverified chemical infoboxes ●Drugs that are a monoclonal antibody ●All stub articles ●This page was last edited on 4 September 2023, at 21:38 (UTC). ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Mobile view